Skip to main content

Advertisement

SpringerLink
Log in

Current topics in therapeutic plasmapheresis

  • Review Article
  • Published:
Clinical and Experimental Nephrology Aims and scope Submit manuscript

Abstract

Therapeutic plasmapheresis has been used for intractable diseases that cannot be cured by conventional drug therapy. Currently, the use of therapeutic plasmapheresis has been approved for 27 diseases by Japan’s National Health Insurance system and is mainly categorized into three modalities: plasma exchange (PE), double-filtration plasmapheresis (DFPP), and plasma adsorption (PA). Plasma separators and/or fractionators are essential for the therapy. PE is performed for two purposes: removal of pathogenic antigens or substances in the plasma fraction and supplementation of essential factors, such as albumin and coagulation factors. PE can be used for thrombotic microangiopathy and acute hepatic failure. DFPP can be performed for selective removal of macromolecules while avoiding the use of substitution fluid (i.e., albumin or fresh frozen plasma). DFPP has now been used for conditions involving relatively larger plasma molecules, including hyperviscosity syndrome and ABO-incompatible kidney transplantation. PA can specifically remove pathogenic agents, such as low-density lipoprotein or autoantibodies, in the IgG fractions by the adsorption column and does not require substitution fluids. PA has now been used for a wide variety of neurological diseases, including chronic inflammatory demyelinating polyneuropathy. This review describes the characteristics of each modality, seeking to improve the efficacy and specificity of removal of the target substance.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Graw RG Jr, Herzig GP, Eisel RJ, Perry S. Leukocyte and platelet collection from normal donors with the continuous flow blood cell separator. Transfusion. 1971;11:94–101.

    Article  PubMed  Google Scholar 

  2. Liégeois A, Escourrou J, Ouvré E, Charreire J. Microchimerism: a stable state of low-ratio proliferation of allogeneic bone marrow. Transplant Proc. 1977;9:273–6.

    PubMed  Google Scholar 

  3. Sueoka A. Present status of apheresis technologies: part 1. Membrane plasma separator. Ther Apher. 1997;1:42–8.

    Article  CAS  PubMed  Google Scholar 

  4. Kaplan AA. Therapeutic plasma exchange: core curriculum 2008. Am J Kidney Dis. 2008;52:1180–96.

    Article  PubMed  Google Scholar 

  5. Szczepiorkowski ZM, Winters JL, Bandarenko N, Kim HC, Linenberger ML, Marques MB, Apheresis Applications Committee of the American Society for Apheresis, et al. Guidelines on the use of therapeutic apheresis in clinical practice–evidence-based approach from the Apheresis Applications Committee of the American Society for Apheresis. J Clin Apher. 2010;25:83–177.

    Article  PubMed  Google Scholar 

  6. Fuss M, Bagon J, Dupont E, Manderlier T, Brauman H, Corvilain J. Parathyroid hormone and calcium blood levels in acute renal failure. With special reference to one patient developing transient hypercalcemia. Nephron. 1978;20:196–202.

    Article  CAS  PubMed  Google Scholar 

  7. Brecher ME. Plasma exchange: why we do what we do. J Clin Apher. 2002;17:207–11.

    Article  PubMed  Google Scholar 

  8. Balogun RA, Ogunniyi A, Sanford K, Okafor C, Lobo PI, Siami G, Barcia J, Kaplan AA. Therapeutic apheresis in special populations. J Clin Apher. 2010;25:265–74.

    Article  PubMed  Google Scholar 

  9. McLeod BC. Therapeutic apheresis: use of human serum albumin, fresh frozen plasma and cryosupernatant plasma in therapeutic plasma exchange. Best Pract Res Clin Haematol. 2006;19:157–67.

    Article  CAS  PubMed  Google Scholar 

  10. Crookston KP, Simon TL. Physiology of apheresis. In: McLeod BC, editor. Apheresis principles and practice. Bethesda: AABB Press; 2003. p. 71–93.

    Google Scholar 

  11. Chopek M, McCullough J. Protein and biochemical changes during plasma exchange. In: Berkman EM, Umlas J, editors. Therapeutic Hemapheresis. Washington, DC: American Association of Blood Banks; 1980. p. 13–52.

    Google Scholar 

  12. Weinstein R. Basic priciples pf therapeutic Blood exchange. In: Mcleod BC, Price TH, Weinstein R, editors. Apheresis: principles and practice. 2nd ed. Bethesda: AABB Press; 2003. p. 295–320.

    Google Scholar 

  13. Haddad S, Leitman SF, Wesley RA, Cecco S, Yau YY, Starling J, Rehak NN, Bolan CD. Placebo-controlled study of intravenous magnesium supplementation during large-volume leukapheresis in healthy allogeneic donors. Transfusion. 2005;45:934–44.

    Article  CAS  PubMed  Google Scholar 

  14. Moake JL. Thrombotic microangiopathies. N Engl J Med. 2002;347:589–600.

    Article  CAS  PubMed  Google Scholar 

  15. Fujimura Y, Matsumoto M. Registry of 919 patients with thrombotic microangiopathies across Japan: database of Nara Medical University during 1998–2008. Intern Med. 2010;49:7–15.

    Article  PubMed  Google Scholar 

  16. Bell WR, Braine HG, Ness PM, Kickler TS. Improved survival in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Clinical experience in 108 patients. N Engl J Med. 1991;325:398–403.

    Article  CAS  PubMed  Google Scholar 

  17. Rock GA, Shumak KH, Buskard NA, Blanchette VS, Kelton JG, Nair RC, Spasoff RA. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group. N Engl J Med. 1991;325:393–7.

    Article  CAS  PubMed  Google Scholar 

  18. Bruce C, McLeod MD. Therapeutic plasma exchange. In: Winters JL, editor. Therapeutic apheresis: a physicians’s handbook. 2nd ed. Bathesda: American Society for Apheresis (ASFA); 2008. p. 69–134.

  19. Stravitz RT. Critical management decisions in patients with acute liver failure. Chest. 2008;134:1092–102.

    Article  PubMed  Google Scholar 

  20. Clemmesen JO, Kondrup J, Nielsen LB, Larsen FS, Ott P. Effects of high-volume plasmapheresis on ammonia, urea, and amino acids in patients with acute liver failure. Am J Gastroenterol. 2001;96:1217–23.

    Article  CAS  PubMed  Google Scholar 

  21. De Silvestro G, Marson P, Brandolese R, Pittoni G, Ongaro G. A single institution’s experience (1982–1999) with plasma-exchange therapy in patients with fulminant hepatic failure. Int J Artif Organs. 2000;23:454–61.

    PubMed  Google Scholar 

  22. Singer AL, Olthoff KM, Kim H, Rand E, Zamir G, Shaked A. Role of plasmapheresis in the management of acute hepatic failure in children. Ann Surg. 2001;234:418–24.

    Article  CAS  PubMed  Google Scholar 

  23. Agishi T, Kaneko I, Hasuo Y, Hayasaka Y, Sanaka T, Ota K, et al. Double filtration plasmapheresis. Trans Am Soc Artif Intern Organs. 1980;26:406–11.

    CAS  PubMed  Google Scholar 

  24. Mineshima M, Akiba T. Double filtration plasmapheresis in critical care. Ther Apher. 2002;6:180–3.

    Article  PubMed  Google Scholar 

  25. Sueoka A. Present status of apheresis technologies: part 2. Membrane plasma fractionator. Ther Apher. 1997;1:135–46.

    Article  CAS  PubMed  Google Scholar 

  26. Ichimaru N, Takahara S. Japan’s experience with living-donor kidney transplantation across ABO barriers. Nat Clin Pract Nephrol. 2008;4:682–92.

    Article  PubMed  Google Scholar 

  27. Morelli F, Carlier P, Giannini G, De Luigi MC, Dejana AM, Ruzzenenti MR. Hypercholesterolemia and LDL apheresis. Int J Artif Organs. 2005;28:1025–31.

    CAS  PubMed  Google Scholar 

  28. Klingel R, Mausfeld P, Fassbender C, Goehlen B. Lipidfiltration–safe and effective methodology to perform lipid-apheresis. Transfus Apher Sci. 2004;30:245–54.

    Article  PubMed  Google Scholar 

  29. Batocchi AP, Evoli A, Di Schino C, Tonali P. Therapeutic apheresis in myasthenia gravis. Ther Apher. 2000;4:275–9.

    Article  CAS  PubMed  Google Scholar 

  30. Inoue N, Kunishige M, Yoshida S, Oshima Y, Ohnishi Y, Kuroda Y, et al. Dissociation between titer of anti-ganglioside antibody and severity of symptoms in a case of Guillain-Barré syndrome with treatment-related fluctuation. J Neurol Sci. 2003;210:105–8.

    Article  CAS  PubMed  Google Scholar 

  31. Shimmura H, Tanabe K, Ishikawa N, Tokumoto T, Takahashi K, Toma H. Role of anti-A/B antibody titers in results of ABO-incompatible kidney transplantation. Transplantation. 2000;70:1331–5.

    Article  CAS  PubMed  Google Scholar 

  32. Shimmura H, Tanabe K, Ishida H, Tokumoto T, Ishikawa N, Miyamoto N, et al. Lack of correlation between results of ABO-incompatible living kidney transplantation and anti-ABO blood type antibody titers under our current immunosuppression. Transplantation. 2005;80:985–8.

    Article  CAS  PubMed  Google Scholar 

  33. Hirata N, Kuriyama T, Yamawaki N. Immusorba TR and PH. Ther Apher Dial. 2003;7:85–90.

    Article  CAS  PubMed  Google Scholar 

  34. Asahi T, Yamamoto T, Kutsuki H. Blood purification therapies using dextran sulfate cellulose columns Liposorber and Selesorb. Ther Apher Dial. 2003;7:73–7.

    Article  PubMed  Google Scholar 

  35. Krieter DH, Steinke J, Kerkhoff M, Fink E, Lemke HD, Zingler C, Müller GA, Schuff-Werner P. Contact activation in low-density lipoprotein apheresis systems. Artif Organs. 2005;29:47–52.

    Article  CAS  PubMed  Google Scholar 

  36. Owen HG, Brecher ME. Atypical reactions associated with use of angiotensin-converting enzyme inhibitors and apheresis. Transfusion. 1994;34:891–4.

    Article  CAS  PubMed  Google Scholar 

  37. Kojima S, Harada-Shiba M, Yamamoto A. Plasma constituents other than low-density lipoprotein adsorbed by dextran-sulfate column. Ther Apher. 1997;1:309–13.

    Article  CAS  PubMed  Google Scholar 

  38. Jiménez-Klingberg C, Borberg H. Comparison of protein A- and tryptophan-conjugated polyvinyl alcohol gel columns with an anti-human immunoglobulin antibody adsorber. Current advances in therapeutic plasmapheresis. London: Churchill Livingstone; 1996. p. 83–93.

    Google Scholar 

  39. Rødgaard A, Nielsen FC, Djurup R, Somnier F, Gammeltoft S. Acetylcholine receptor antibody in myasthenia gravis: predominance of IgG subclasses 1 and 3. Clin Exp Immunol. 1987;67:82–8.

    PubMed Central  PubMed  Google Scholar 

  40. McConville J, Farrugia ME, Beeson D, Kishore U, Metcalfe R, Newsom-Davis J, Vincent A. Detection and characterization of MuSK antibodies in seronegative myasthenia gravis. Ann Neurol. 2004;55:580–4.

    Article  CAS  PubMed  Google Scholar 

  41. Yamazaki Z, Fujimori Y, Takahama T, Inoue N, Wada T, Kazama M, Morioka M, Abe T, Yamawaki N, Inagaki K. Efficiency and biocompatibility of a new immunosorbent. Trans Am Soc Artif Intern Organs. 1982;28:318–23.

    CAS  PubMed  Google Scholar 

  42. Tsuboi Y, Takahashi M, Ishikawa Y, Okada H, Yamada T. Elevated bradykinin and decreased carboxypeptidase R as a cause of hypotension during tryptophan column immunoabsorption therapy. Ther Apher. 1998;2:297–9.

    Article  CAS  PubMed  Google Scholar 

  43. Gwathmey K, Balogun RA, Burns T. Neurologic indications for therapeutic plasma exchange: an update. J Clin Apher. 2011;26:261–8.

    Article  PubMed  Google Scholar 

  44. Lehmann HC, Hartung HP, Hetzel GR, Stüve O, Kieseier BC. Plasma exchange in neuroimmunological disorders: part 2. Treatment of neuromuscular disorders. Arch Neurol. 2006;63:1066–71.

    Article  PubMed  Google Scholar 

  45. Hahn AF, Bolton CF, Pillay N, Chalk C, Benstead T, Bril V, Shumak K, Vandervoort MK, Feasby TE. Plasma-exchange therapy in chronic inflammatory demyelinating polyneuropathy. A double-blind, sham-controlled, cross-over study. Brain. 1996;119:1055–66.

    Article  PubMed  Google Scholar 

  46. Dyck PJ, Daube J, O’Brien P, Pineda A, Low PA, Windebank AJ, Swanson C. Plasmaexchange in chronic inflammatory demyelinating polyradiculoneuropathy. N Engl J Med. 1986;314:461–5.

    Article  CAS  PubMed  Google Scholar 

Download references

Conflict of interest

The authors declared no competing interests.

Author information

Authors and Affiliations

  1. Division of Kidney and Dialysis, Department of Internal Medicine, Hyogo College of Medicine, 1-1 Mukogawa-cho, Nishinomiya, 663-8501, Japan

    Takeshi Nakanishi, Naoki Suzuki, Takahiro Kuragano, Yasuyuki Nagasawa & Yukiko Hasuike

Authors
  1. Takeshi Nakanishi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Naoki Suzuki
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Takahiro Kuragano
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yasuyuki Nagasawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yukiko Hasuike
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Takeshi Nakanishi.

Additional information

T. Nakanishi and N. Suzuki contributed equally to this work.

About this article

Cite this article

Nakanishi, T., Suzuki, N., Kuragano, T. et al. Current topics in therapeutic plasmapheresis. Clin Exp Nephrol 18, 41–49 (2014). https://doi.org/10.1007/s10157-013-0838-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10157-013-0838-0

Keywords

Search

Navigation